Physician profile
Joseph T Bergs
NPI 1922038900
$346,479.22
in general payments reported to CMS, 2019-2025
11 companies · $71K in 2025
The $71K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,905 · 2020: $3,697 · 2021: $40K · 2022: $66K · 2023: $74K · 2024: $90K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $165K · Honoraria: $28K · Consulting Fee: $23K · Travel and Lodging: $14K · Food and Beverage: $5,385 · Education: $32.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $164,975.00 |
| Honoraria | $27,650.00 |
| Consulting Fee | $23,090.00 |
| Travel and Lodging | $13,965.51 |
| Food and Beverage | $5,384.84 |
| Education | $32.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $132,403.84 | 2021-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $113,640.99 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $34,439.39 | 2021-2023 | Lybalvi |
| Vanda Pharmaceuticals INC. | $27,885.88 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $24,243.80 | 2022-2025 | Auvelity |
| Allergan, INC. | $8,077.72 | 2019-2021 | |
| Corium, LLC | $5,191.88 | 2023-2024 | Azstarys, Azstarys |
| Janssen Pharmaceuticals, INC | $224.50 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $189.07 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $120.65 | 2023 | Quviviq |
| Neuronetics, INC. | $61.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Bergs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.